FDA approves 1st mRNA flu shot, from Moderna

There are no new alerts at this time The Food and Drug Administration on Wednesday approved the U.S.’ first flu shot that uses mRNA technology: mFlusiva, from drugmaker Moderna. The FDA granted approval for two age groups, adults 50 to 65 and adults 65 and up, on the condition that Moderna run an additional clinical trial in the older group, the company said in a release. In a late-stage trial, mFlusiva was found to be about 27% more effective than a standard flu shot. Many scientists and public health experts have touted the idea of an mRNA-based flu vaccine, which uses the same messenger RNA platform as the Covid vaccines from Moderna and Pfizer. That’s because mRNA vaccines can be manufactured much faster than traditional vaccines, allowing scientists to better match circulating influenza strains.

Missing media or need the complete publisher report? Open NBC News ↗